Albumin Patents (Class 530/362)
-
Patent number: 6787636Abstract: A modified serum albumin is provided which has been modified in the n-terminal region or binding region VI, such as through a truncation of at least one amino acid at the n-terminal end, so that it exhibits reduced or eliminated binding of trace metals such as nickel and/or copper. Other suitable modifications to this binding region include mutations such as an elongation or insertion which will be sufficient to disrupt the trace metal binding which is highest at this site. The modified albumin of the present invention is advantageous in that it is binding to trace metals is reduced or eliminated, and it can thus be used more safely and effectively than unmodified albumin with a reduced or eliminated likelihood of causing an allergic reaction to the trace metal in the human being treated with the albumin composition.Type: GrantFiled: July 14, 2000Date of Patent: September 7, 2004Assignee: New Century Pharmaceuticals, Inc.Inventor: Daniel C. Carter
-
Publication number: 20040116673Abstract: A novel class of compounds, i.e., 1,1-bis-H-phosphinates (or 1,1-bis-H-phosphinic acid derivatives) are provided. Also provided are novel methods for producing 1,1-bis-H-phosphinates and 1,1-bis-H-phosphinate conjugates. These compounds and conjugates are used as precursors of bisphosphonates and bisphosphonate conjugates, respectively, or as prodrugs directly for treating bone-related and various other diseases.Type: ApplicationFiled: December 13, 2002Publication date: June 17, 2004Applicant: Texas Christian UniversityInventors: Jean-Luc Montchamp, Sylvine Deprele
-
Patent number: 6719990Abstract: The present invention provides compositions which allow for the extended release and enhanced bioavailability of biologically-active polypeptides following parenteral delivery to an animal. More particularly, it concerns compositions comprising biologically-active somatotropin formulated for extended release, methods of preparing these compositions, and methods of using the same. These compositions comprise somatotropin, a bioavailability-enhancing constituent (BEC), and a substantially non-aqueous, hydrophobic excipient. The BEC may comprise (i) amino acids or amino acid derivatives, such as histidine-HCl; (ii) hydroxamate derivatives, such as histidine hydroxamate or suberohydroxamic acid; (iii) non-reducing carbohydrates, such as trehalose or trehalose octaacetate; (iv) oxo-acid salts, such as a mixture of monobasic and dibasic sodium phosphate; or (v) a mixture of two or more compounds from within the foregoing classes (i)-(iv).Type: GrantFiled: February 21, 2001Date of Patent: April 13, 2004Assignee: Monsanto Technology LLCInventors: Kanaiyalal R. Patel, Yunhua N. Jeng
-
Patent number: 6719992Abstract: The present invention provides compositions comprising biologically-active somatotropin formulated for extended release and methods of preparing and methods of using the same. These compositions comprise somatotropin, at least a first bioavailability-enhancing constituent (BEC), and a substantially non-aqueous, hydrophobic excipient, and optionally a second BEC. The first BEC is typically a surfactant (preferably a non-ionic surfactant) or a cyclodextrin compound. The optional second BEC may comprise (i) amino acids or amino acid derivatives; (ii) hydroxamate derivatives; (iii) non-reducing carbohydrates; (iv) oxo-acid salts; or (v) a mixture of two or more compounds from within the foregoing classes (i)-(iv).Type: GrantFiled: June 26, 2001Date of Patent: April 13, 2004Assignee: Monsanto Technology LLCInventors: Yunhua N. Jeng, Kanaiyalal R. Patel
-
Patent number: 6706690Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: GrantFiled: June 10, 1999Date of Patent: March 16, 2004Assignee: Baxter Healthcare CorporationInventors: Cary J. Reich, A. Edward Osawa, Helen Tran
-
Patent number: 6693173Abstract: A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about 10, and diafiltering the pH-adjusted solution against aqueous solutions which have a low level of ions.Type: GrantFiled: March 13, 2001Date of Patent: February 17, 2004Assignee: Alpha Therapeutic CorporationInventors: Raja R. Mamidi, Leticia R. Regis, Mauro C. Mojica, Hirokazu Ito, Takashi Goto
-
Patent number: 6693169Abstract: The present invention features two members of laminin family, i.e., laminin 13 and laminin 14, the methods of making these molecules, and the methods of using these molecules in treating neural disorders, e.g., retinal disorders. The present invention also features using a preparation of laminin 5 to treat neural disorders, especially disorders associated with retina.Type: GrantFiled: October 12, 1999Date of Patent: February 17, 2004Assignee: The General Hospital CorporationInventors: William J. Brunken, Richard R. Libby, Dale D. Hunter, Robert E. Burgeson
-
Patent number: 6686179Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.Type: GrantFiled: October 29, 2001Date of Patent: February 3, 2004Assignee: Aventis Behring L.L.C.Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, GĂ©rard Jung, Patrice Yeh
-
Publication number: 20030219875Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 12, 2001Publication date: November 27, 2003Inventors: Craig A. Rosen, William A. Haseltine
-
Patent number: 6638740Abstract: The present invention relates to a process for purifying the protein human serum albumin extracted from serum or recombinant human albumin produced by transforming a microorganism with a nucleotide coding sequence encoding the amino acid sequence of human serum albumin. The present invention provides highly purified albumin.Type: GrantFiled: February 24, 1999Date of Patent: October 28, 2003Assignee: Delta Biotechnology Ltd.Inventors: Andrew Robert Goodey, Darrell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
-
Publication number: 20030191292Abstract: Filtration methods comprise virus-filtering a solution containing a least one macromolecule. The total salt content of the solution for virus-filtering is within the range of from about 0.2 M up to saturation with the salt. Salts that can be used in the filtering methods include sodium chloride, potassium chloride, sodium acetate, sodium citrate, sodium phosphate, potassium dyhydrophosphate and combinations thereof.Type: ApplicationFiled: November 26, 2002Publication date: October 9, 2003Applicant: Octapharma AG, a Corporation of SwitzerlandInventor: Stefan Winge
-
Publication number: 20030187226Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin (for example using blue dyes) and affinity chromatography binding contaminants (for example using an aminophenylboronic acid resin). Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.Type: ApplicationFiled: November 21, 2002Publication date: October 2, 2003Inventors: Andrew Robert Goodey, Darrell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
-
Patent number: 6620778Abstract: Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained in step a) by an exopeptidase, the action of which is at least attenuated at the position of a cysteine in the peptide, therewith forming digested peptides having a terminal cysteine; c) purifying the digested peptides, and the use of the preparation as active component in a medicament, especially for the treatment of conditions mediated by oxidative damage and for the elevation of cellular glutathion levels in the human or animal body.Type: GrantFiled: October 23, 2001Date of Patent: September 16, 2003Assignee: Campina Melkunie B.V.Inventors: Leon Franciscus Mallee, Ram Nimmagudda, Johannes Wilhelmus L. Boumans
-
Patent number: 6613884Abstract: A method for removing a serum albumin from a mixture of other compounds by contacting said mixture with a ligand a) having affinity for and enabling selective binding of the serum albumin and b) being attached to a base matrix insoluble in the aqueous media used or being possible to attach to such a matrix after having become bound to the serum albumin, characterized in that said ligand is derived from an albumin binding bacterial cell surface receptor and that the ligand lacks the IgG-binding and/or &agr;2-macroglobulin-binding ability found in native forms of these type of bacterial receptors. An albumin-binding ligand derived from a cell surface bacterial receptor and attached covalently to a carrier matrix, characterized in that the ligand is monovalent with respect to ability to bind a serum albumin. A method for removal of serum albumin from a sample that is to be assayed for non-serum albumin components.Type: GrantFiled: February 15, 2001Date of Patent: September 2, 2003Assignee: Amersham Biosciences ABInventor: Hans Johansson
-
Patent number: 6610825Abstract: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system.Type: GrantFiled: March 1, 2001Date of Patent: August 26, 2003Assignee: ConjuChem, Inc.Inventors: Alan M. Ezrin, Dominique P. Bridon, Darren L. Holmes, Peter G. Milner
-
Patent number: 6602981Abstract: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity.Type: GrantFiled: March 1, 2001Date of Patent: August 5, 2003Assignee: ConjuChem, Inc.Inventors: Alan M. Ezrin, Dominique P. Bridon, Darren L. Holmes, Peter G. Milner
-
Publication number: 20030004316Abstract: Disclosed is a method of fractionating &agr;-lactalbumin from &bgr;-lactoglobulin in whey or whey protein concentrate. The method includes the steps of contacting whey or whey protein concentrate with a complexing agent so that the complexing agent forms insoluble complexes with &bgr;-lactoglobulin present in the whey or whey protein concentrate. The insoluble complexes are then separated from the whey or whey protein concentrate, thus yielding a precipitate that is predominately &bgr;-lactoglobulin and is substantially devoid of &agr;-lactalbumin, and a supernatant that predominately &agr;-lactalbumin and is substantially devoid of &bgr;-lactoglobulin.Type: ApplicationFiled: March 12, 2002Publication date: January 2, 2003Inventors: Leorges M. Da Fonseca, Robert L. Bradley
-
Patent number: 6500800Abstract: The present invention is directed to a composition for causing photodynamic damage to target cells comprising a photosensitiser, a photosensitiser carrier component, a component which enables target cell recognition and transport of the photosensitiser toward the interior of the target cell by specific receptor-mediated endocytosis, and a component capable of effective targeted transport of the photosensitiser within the target cells. The invention is also related to a method for causing photodynamic damage to target cells comprising the steps of: adding the composition to the cells; keeping the cells at a temperature of normal vital activity of cells with the composition for causing photodynamic damage to the target cells, said composition comprising the above-mentioned components; and exposure of the cells to light.Type: GrantFiled: August 12, 1998Date of Patent: December 31, 2002Inventors: Alexander Sergeevich Sobolev, Andrei Alexandrovich Rozenkrants, Tamara Vladimirovna Akhlynina, David Andrew Jans
-
Patent number: 6500918Abstract: Conjugates are prepared from antinociceptive agents, particularly opioids or opioid analogs, more particularly dynorphins, endorphins, deltorphins, enkephalins or analogs thereof, by combining said antinociceptive agent with a material providing a functionally reactive group capable of reacting with a blood component (preferably a blood cell or protein). Said conjugates permit extension of the therapeutic life of the antinociceptive agent. They may be administered to patients to alleviate pain, produce analgesic effects, or assist in cases of narcotics withdrawal, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the derivative including the reactive functional group into the patient's vascular system or preparing such a conjugate externally (or in vitro) and introducing that conjugate to the patient's vascular system.Type: GrantFiled: March 1, 2001Date of Patent: December 31, 2002Assignee: Conjuchem, Inc.Inventors: Alan M. Ezrin, Dominique P. Bridon, Darren L. Holmes, Peter G. Milner
-
Patent number: 6489443Abstract: A process for the preparation of a protein solution is described which is not prone to flock or particle formation even on heat treatment, the heat treatment being carried out in a glass vessel which has been rinsed out beforehand with a detergent solution and then with distilled water or another detergent-free solvent.Type: GrantFiled: July 9, 1999Date of Patent: December 3, 2002Assignee: Aventis Behring GmbHInventors: Jürgen Römisch, Jörg Weisse, Jean Luc Veron, Juliana Djordjevich, Wilfried Freudenberg, Michel Grandgeorge, Barbara Kalina, Peter Kappus, Manfred Konrad, Gregory S. Rood, Werner Thill
-
Patent number: 6485935Abstract: The present invention provides a polypeptide of 26 amino acid residues that comprises the minimal ankyrin binding (MAB) domain. The MAB domain is responsible for the interactions between a Na,K-ATPase and ankyrin. The present invention also provides the three dimensional structure of the MAB domain. Also provided by the present invention are methods for modulating the interaction of a Na,K-ATPase and ankyrin.Type: GrantFiled: January 11, 2000Date of Patent: November 26, 2002Assignee: Yale UniversityInventors: Jon S. Morrow, Prasad Devarajan, Zhushan Zhang
-
Patent number: 6458758Abstract: Compositions and processes to alleviate free radical toxicity are disclosed based on the use of nitroxides in association with physiologically compatible macromolecules. In particular, hemoglobin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. Formulations are described herein that interact with free radicals, acting as antioxidant enzyme-mimics, which preserve nitroxides in their active form in vivo. Applications are described including blood substitutes, radioprotective agents, imaging agents, agents to protect against ischemia and reperfusion injury, particularly in cerebral ischemia in stroke, and in vivo enzyme mimics among others.Type: GrantFiled: March 26, 1997Date of Patent: October 1, 2002Assignee: Synzyme Technologies, Inc.Inventor: Jen-Chang Hsia
-
Patent number: 6429297Abstract: The present invention relates to a compound of the formula These modified streptavidin compounds have are useful as part of a delivery system to deliver a molecule to a target site for use in diagnosis or therapy.Type: GrantFiled: February 3, 2000Date of Patent: August 6, 2002Assignee: University of RochesterInventor: Scott F. Rosebrough
-
Patent number: 6429294Abstract: A peritoneal dialysis fluid used for a continuous recirculating peritoneal dialysis wherein the peritoneal dialysis fluid is infused into a peritoneal cavity of a patient and then, typically on a continuous process basis a portion of the dialysis fluid is sequentially drained from the cavity, cleansed through an extracorpreal dialyzer, and reinfused into the cavity. The dialysis fluid contains as an osmotic agent a substance which does not substantially permeate through pores of hollow fiber membrane of an extracorporeal dialyzer, preferably an osmotic agent having a molecular weight of about 20,000 to about 100,000. The supplemented amount of the osmotic agent is reduced or not needed during the dialysis.Type: GrantFiled: June 17, 1999Date of Patent: August 6, 2002Assignee: Nipro CorporationInventors: Toshiaki Masuda, Hidetoshi Yamamoto
-
Publication number: 20020102659Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: ApplicationFiled: January 9, 2002Publication date: August 1, 2002Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 6410695Abstract: The present invention relates to a conjugate comprising an active substance and a compound having a binding site for metallic compounds. In addition, this invention relates to a process for the preparation of such a conjugate and its use.Type: GrantFiled: February 9, 1998Date of Patent: June 25, 2002Assignee: Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen RechtsInventors: Hannsjörg Sinn, Wolfgang Maier-Borst, Hans-Hermann Schrenk, Gerd Stehle
-
Publication number: 20020045582Abstract: This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition.Type: ApplicationFiled: August 10, 1999Publication date: April 18, 2002Inventors: ALEXEY L. MARGOLIN, NAZAR K. KHALAF, NANCY L. ST. CLAIR, SCOTT L. RAKESTRAW, BHAMI C. SHENOY
-
Patent number: 6372794Abstract: A method for alleviating arthritis in mammals by the oral administration of a pharmaceutical composition compound of native Type II collagen in helical form and sulfated polysaccharides found in mammalian cartilage, the Type II collagen and sulfated polysaccharides being ionically bound.Type: GrantFiled: August 26, 1999Date of Patent: April 16, 2002Inventor: Marcel E. Nimni
-
Patent number: 6372510Abstract: The present invention is drawn to method for removing unconventional transmissible agents (UCTA) from aqueous protein solution. This method involves treating the aqueous protein solution with simultaneous electrostatic adsorption and hydrophobic chromatography. The method of the present invention is particularly suitable for treating calf serum or an albumin solution.Type: GrantFiled: November 10, 1998Date of Patent: April 16, 2002Assignee: Pasteur Merieux Serum et VaccinsInventors: Michel Grandgeorge, René Labatut, Jean-Marc Rouzioux, Jean-Louis Tayot, Jean-Luc Veron
-
Publication number: 20020042378Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: ApplicationFiled: June 10, 1999Publication date: April 11, 2002Inventors: CARY J. REICH, A. EDWARD OSAWA, HELEN TRAN
-
Publication number: 20020037254Abstract: The invention relates to conjugates, comprising a fluorescent compound and a carrier, wherein the compound and the carrier are connected via an acidic ester or an acidic amide bond and the compound has an excitation wavelength of 630 nm or more and/or 450 nm or less. The invention also relates to the production of said conjugates and to the use thereof.Type: ApplicationFiled: August 4, 2000Publication date: March 28, 2002Inventors: HANNSJORG SINN, HANS-HERMANN SCHRENK, ANDREAS WUNDER, GERD STEHLE
-
Patent number: 6358918Abstract: There is disclosed a stable, virus-safe, pharmaceutical preparation comprising thiol-group-containing proteins which are heat-treated and processed such that at least 40% of the thiol groups are capable of being nitrosated, a method of preparing such preparations as well as the use of these preparations.Type: GrantFiled: July 5, 2000Date of Patent: March 19, 2002Assignee: Baxter AktiengesellschaftInventors: Guenther Schlag, Seth Hallstroem, Harald Gasser
-
Patent number: 6350601Abstract: Disclosed is a stabilized enzyme composition for use in clinical examination, comprising: (a) an enzyme component comprising at least two enzymes selected from the group consisting of alkaline phosphatase, creatine kinase and alanine aminotransferase; (b) a stabilizer component comprising effective stabilizing amounts of an albumin, and at least one saccharide selected from the group consisting of trehalose and sorbitol; and (c) an aqueous medium having dissolved therein the components (a) and (b). The enzyme composition of the present invention is stable for a prolonged period of time not only under non-freeze refrigeration conditions, but also under freezing conditions or under conditions for non-freeze refrigeration after thawing of the frozen composition, as compared to the conventional enzymatic compositions.Type: GrantFiled: May 8, 1997Date of Patent: February 26, 2002Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Ryoji Aoki, Shigeru Ueda
-
Publication number: 20020019343Abstract: Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS—, HO— or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5′-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=—NH2, —OH, —COOH, —O—CO—R—COR*, —NH—CO—R—COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.Type: ApplicationFiled: August 20, 2001Publication date: February 14, 2002Inventor: Felix Kratz
-
Publication number: 20020012906Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease, followed by early drug intervention to prevent and treat the disease are also disclosed. The drug treatment involves the use of a lysosome activating compound.Type: ApplicationFiled: June 28, 2001Publication date: January 31, 2002Inventor: Wayne D. Comper
-
Publication number: 20020009790Abstract: A process is described wherein there is added to an acidic environment, which contains protein, a block-wise enzymatically de-esterified pectin, and wherein the pectin is a high ester pectin. Also described is a recombinant pectin methyl esterase.Type: ApplicationFiled: March 16, 2001Publication date: January 24, 2002Inventors: Tove Martel Ida Elsa Christensen, Jette Dina Kreiberg, Hanne Thorsoe, Hans Christian Buchholt, Preben Rasmussen, John Nielsen
-
Patent number: 6329337Abstract: An adhesive for biological tissue includeds: a glue agent and a cross-linking agent. The glue agent contains a recombinant human plasma protein as a main component. The cross-linking agent contains a bifunctional or multifunctional aldehyde as a main component.Type: GrantFiled: April 6, 2000Date of Patent: December 11, 2001Assignee: Toyo Boseki Kabushiki KaishaInventors: Yasunobu Morita, Ken Murayama
-
Patent number: 6310036Abstract: Disclosed is a novel tissue adhesive technology comprising a combination of ultrasonically treated proteins including collagen and albumin which form a viscous material that develops adhesive properties when chemically cross-linked. A novel new cross-linking agent with surprisingly stable properties was developed in association with the tissue adhesive described and claimed herein and is considered to be within the scope of the present invention. This new cross-linking agent is a product of reacting glutaraldehyde with amino acids or peptides and allowing the reaction to proceed to completion. This chemical cross-linker is mixed with the ultrasonically treated proteins, allowed to react for a pre-determined time, then used to seal large surface areas of vigorously bleeding tissues including, but not limited to, the liver, lungs and major vascular systems in patients with and without bleeding disorders. This same tissue adhesive has proven to work well in sealing suture sites to prevent leakage.Type: GrantFiled: January 9, 1999Date of Patent: October 30, 2001Assignee: Last Chance Tissue Adhesives CorporationInventor: David A. Browdie
-
Publication number: 20010012885Abstract: This invention relates to a conjugate which consists of an active substance and a native protein which is not regarded as exogenous and distinguishes itself in that an intracellularly cleavable linker is present between the active substance and the protein.Type: ApplicationFiled: April 4, 2001Publication date: August 9, 2001Applicant: Deutsches Krebsforschungszentrum stiftung des Offentlichen RechtsInventors: Hansjorg Sinn, Hans-Hermann Schrenk, Wolfgang Maier-Borst, Gerd Stehle, Andreas Wunder, Dirk Hoff-Biederbeck, Dieter Ludwig Heene
-
Patent number: 6252087Abstract: Nitroaromatic compounds and immunogenic conjugates comprising a novel nitroaromatic compound and a carrier protein are disclosed. The invention further presents monoclonal antibodies highly specific for the claimed nitroaromatic compounds, the compounds' protein conjugates, the compounds' reductive byproducts, and adducts formed between the compounds and mammalian hypoxic cell tissue proteins. The invention is further directed to methods for detecting tissue hypoxia using immunohistological techniques, non-invasive nuclear medicinal methods, or nuclear magnetic resonance. Diagnostic kits useful in practicing the methods of claimed invention are also provided.Type: GrantFiled: July 28, 1998Date of Patent: June 26, 2001Assignee: The Trustees of the University of PennsylvaniaInventors: Cameron J. Koch, Alexander V. Kachur, Sydney M. Evans, Chyng-Yann Shiue, Ian R. Baird, Kirsten A. Skov, William R. Dolbier, Jr., An-Rong Li, Brian R. James
-
Patent number: 6211335Abstract: A method for joining tissue comprising aligning and abutting edges of the tissue to be joined applying biodegradable, biological solder or an analogue thereof, across the edges and exposing the solder to an energy source under conditions which provide transfer of energy from the source to the solder to cause the solder to bond to the tissue surface adjacent the edges to provide a weld holding the edges together.Type: GrantFiled: October 17, 1997Date of Patent: April 3, 2001Assignees: The Microsearch Foundation of Australia, Macquarie Research Ltd.Inventors: Earl Ronald Owen, Rodney Ian Trickett, Antonio Lauto, Judith Margaret Dawes, James Austin Piper
-
Patent number: 6187368Abstract: Fat-like protein compositions for use in foods and cosmetics comprising a protein of gelatin and a water-soluble albumin, a carbohydrate, and a phospholipid wherein said gelatin, albumin, carbohydrate, and phospholipids are in the form of a water-insoluble complex coacervate, and processes for making the same. Preferred are compositions wherein some or all of the ingredients are optionally crosslinked.Type: GrantFiled: June 25, 1999Date of Patent: February 13, 2001Inventors: Suzanne M. Gibson, George Strauss
-
Patent number: 6174858Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).Type: GrantFiled: November 17, 1998Date of Patent: January 16, 2001Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, Dong-Mei Feng, Victor M. Garsky
-
Patent number: 6165981Abstract: Disclosed are compositions for stabilizing proteins and fragments of the proteins. The composition contains buffer, salt, reducing agents, chelating agents and stabilizing proteins. The composition may be used to prepare highly stable diagnostic calibrators or controls and is particularly useful for calibrators or controls for cardiac markers such as troponin.Type: GrantFiled: March 7, 1995Date of Patent: December 26, 2000Assignee: Dade Behring Inc.Inventors: Cathy Flaa, Alberto Sabucedo, Bruce Chin, Roger Bauer
-
Patent number: 6107461Abstract: Multimers comprising two or more monomers, wherein said monomers may be the same or different and are each independently selected from the group consisting of transmembrane intercellular adhesion molecule-1 (tmICAM-1) and fragments thereof, with the proviso that said monomers must comprise domains I and II of ICAM-1 and with the proviso that when said multimer is a dimer, the monomers cannot both be tmICAM-1, wherein said multimer binds to a ligand that binds to the human rhinovirus (HRV) binding site on ICAM-1, and wherein at least two of said monomers are oriented so that relative to each other they mimic the multimeric configuration of native tmICAM-1, such that said multimer exhibits enhanced binding to said ligand relative to at least one of its constituent monomers, and methods of use.Type: GrantFiled: October 4, 1994Date of Patent: August 22, 2000Assignee: Bayer CorporationInventors: Jeffrey M. Greve, Alan McClelland
-
Patent number: 6034221Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, fragments of albumin, polymers or aggregates of albumin, and viruses, and which is relatively non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through two chromatography purifications, ultrafiltering the product, passing through two further chromatography steps and again ultrafiltering the product.Type: GrantFiled: November 14, 1997Date of Patent: March 7, 2000Assignee: Delta Biotechnology LimitedInventors: Stephen Berezenko, John R. Woodrow, Richard A. Johnson, Patricia C. Wood, Steven J. Burton, Alan V. Quirk, David St. J. Coghlan, Mark J. Wilson
-
Patent number: 6022858Abstract: A pharmaceutical formulation comprising a growth hormone pretreated with zinc and optionally lysine or calcium ions shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.Type: GrantFiled: July 23, 1998Date of Patent: February 8, 2000Assignee: Novo Nordisk A/SInventors: Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim, Christensen Thorkild, Per Balschmidt
-
Patent number: 6022524Abstract: A process for the preparation of macromolecular chelants characterized by a high content in chelant groups per macromolecule.Type: GrantFiled: April 16, 1998Date of Patent: February 8, 2000Assignee: DIBRA S.p.A.Inventors: Federico Maisano, Luigia Gozzini
-
Patent number: 6008198Abstract: A porphyrin metal complex-albumin inclusion compound wherein a substituted porphyrin metal complex comprising, as a central, coordinated metal, a transitional metal belonging to the fourth or fifth period of the periodic law, is included in the albumin, and an oxygen carrier composition comprising said inclusion compound as an active ingredient. The compound functions as an oxygen carrier which is superior in biocompatibility, capable of adsorption and desorption of oxygen under physiological conditions, and is rather easily produced at an industrial scale.Type: GrantFiled: April 29, 1996Date of Patent: December 28, 1999Assignee: Yoshitomi Pharmaceutical Industries, Ltd.Inventors: Eishun Tsuchida, Hiroyuki Nishide, Teruyuki Komatsu
-
Patent number: RE38158Abstract: This invention is related to an adhesive composition which may be used to bond or seal tissue in vivo. The adhesive composition is readily formed from a two component mixture which includes a first part of a protein, preferably a serum albumin protein, in an aqueous buffer having a pH in the range of about 8.0-11.0 and a second part of a water-compatible or water-soluble bifunctional crosslinking agent. When the two parts of the mixture are combined, the mixture is initially a liquid which cures in vivo on the surface of tissue in less than about one minute to give a strong, flexible, pliant substantive composition which bonds to the tissue and is absorbed in about four to sixty days. The adhesive composition may be used either to bond tissue, to seal tissue or to prevent tissue adhesions caused by surgery.Type: GrantFiled: November 4, 1998Date of Patent: June 24, 2003Assignee: Minnesota Mining and Manufacturing CompanyInventors: Thomas H. Barrows, Terry W. Lewis, Myhanh T. Truong, Matthew T. Scholz